∙ Age:

• The participant is aged 18 years or older at the time of signing the informed consent form (ICF).

• Disease Characteristics:

• The participant has a diagnosis of PsA.

• The participant must have signs and symptoms of PsA for at least 3 months prior to screening.

• The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).

• The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.

• The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

• Medications for PsA:

• The participant has had at least one of the following:

‣ Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union \[EU\]/ European Economic Area \[EEA\]), OR

⁃ Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD), OR

⁃ Biological disease-modifying antirheumatic drug (DMARD)-inadequate response (Bio-IR): Inadequate response to up to 2 biologic DMARDs.